[Diagnostic-therapeutic care pathways for patients with cardiac amyloidosis - SIC/ANMCO Consensus document. Edited by the Italian Cardiac Amyloidosis Network (RIAC)]

G Ital Cardiol (Rome). 2024 Dec;25(12):900-920. doi: 10.1714/4372.43703.
[Article in Italian]

Abstract

The perspective on cardiac amyloidosis has deeply changed over the last 10 years following major advances in diagnosis and treatment options. This heterogeneous disease requires the interaction among experts of different specialties and subspecialties. Suspicion of disease, timely recognition and confirmation of final diagnosis, prognostic stratification, overall management and therapeutic strategies represent ongoing challenges in the clinical setting. Missing or delayed diagnosis may have significant impact on patient outcome, especially in light-chain amyloidosis. The present inter-society consensus document aims to provide a standardized approach to the diagnosis of cardiac amyloidosis in Italy, and to discuss the challenging clinical scenarios encountered in routine activity for cardiologists and physicians of different specialties dealing with patients with suspected or established cardiac amyloidosis. This document may be adapted to the setting of each specific region.

Publication types

  • Consensus Development Conference
  • Practice Guideline
  • English Abstract

MeSH terms

  • Amyloidosis* / diagnosis
  • Amyloidosis* / therapy
  • Cardiomyopathies* / diagnosis
  • Cardiomyopathies* / therapy
  • Critical Pathways
  • Humans
  • Immunoglobulin Light-chain Amyloidosis / diagnosis
  • Immunoglobulin Light-chain Amyloidosis / therapy
  • Italy
  • Prognosis